Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00064610
Status:
COMPLETED
Last Update Posted:
2008-02-11
First Post:
2003-07-10
Brief Title:
Phase III Dose Escalation Study of VELCADE and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer
Sponsor:
Millennium Pharmaceuticals Inc
Organization:
Millennium Pharmaceuticals Inc
Study Overview
Official Title:
A Phase III Open Label Dose Escalation Study to Determine the Tolerance and Preliminary Activity of PS-341 Plus Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer Requiring Chemotherapy
Status:
COMPLETED
Status Verified Date:
2008-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate how safe PS-341VELCADE is when given with Docetaxel Taxotere to patients with androgen-independent prostate cancer and also to see what effects good and bad it has on you and on your cancer
Detailed Description:
This is a dose escalation study which means that the first group of patients will receive a low dose of PS-341 VELCADE and Docetaxel Taxotere If the low dose of VELCADE and Taxotere appears to be safe then the next group of patients will receive a higher dose of VELCADE and Taxotere
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None